You are here: Home Published Research A randomised trial to evaluate the immunogenicity, reactogenicity, and safety of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with routine childhood vaccines in Singapore and Malaysia.

Fong S Lim, Mia T Koh, Kah K Tan, Poh C Chan, Chia Y Chong, Yeo W Shung Yehudi, Yee L Teoh, Fakrudeen Shafi, Marjan Hezareh, Kristien Swinnen, and Dorota Borys (2014)

A randomised trial to evaluate the immunogenicity, reactogenicity, and safety of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with routine childhood vaccines in Singapore and Malaysia.

BMC infectious diseases, 14(1):530.

The immunogenicity, reactogenicity, and safety of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with routine childhood vaccines were evaluated among infants from Singapore and Malaysia, where PHiD-CV has been licensed.

Antibodies, Bacterial, Bacterial Proteins, Carrier Proteins, Female, Humans, Immunization, Secondary, Immunoglobulin D, Infant, Lipoproteins, Malaysia, Male, Pneumococcal Infections, Pneumococcal Vaccines, Polysaccharides, Bacterial, Singapore, Streptococcus pneumoniae, Vaccination, Vaccine Potency, Vaccines, Conjugate
Antibodies, Bacterial, Bacterial Proteins, Carrier Proteins, Female, Humans, Immunization, Secondary, Immunoglobulin D, Infant, Lipoproteins, Malaysia, Male, Pneumococcal Infections, Pneumococcal Vaccines, Polysaccharides, Bacterial, Singapore, Streptococcus pneumoniae, Vaccination, Vaccine Potency, Vaccines, Conjugate
 
Document Actions